Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted : Clinical Experience from a Spanish Cohort of Expanded Use
Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy.
Methods: : A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration.
Results: : Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn't. 10 out of 16 patients responded (＞ 50% change in baseline MADRS scores), but only five achieved remission (＜ 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects.
Conclusion: : Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology - 22(2024), 1 vom: 29. Jan., Seite 159-168 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vendrell-Serres, Júlia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Compassionate use |
|---|
| Anmerkungen: |
Date Revised 28.01.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.9758/cpn.23.1097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367379147 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367379147 | ||
| 003 | DE-627 | ||
| 005 | 20240128231937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.9758/cpn.23.1097 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM367379147 | ||
| 035 | |a (NLM)38247422 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vendrell-Serres, Júlia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted |b Clinical Experience from a Spanish Cohort of Expanded Use |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy | ||
| 520 | |a Methods: : A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration | ||
| 520 | |a Results: : Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn't. 10 out of 16 patients responded (＞ 50% change in baseline MADRS scores), but only five achieved remission (＜ 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects | ||
| 520 | |a Conclusion: : Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Compassionate use | |
| 650 | 4 | |a Depressive disorder | |
| 650 | 4 | |a Esketamine | |
| 650 | 4 | |a Prospective study | |
| 650 | 4 | |a treatment-resistant | |
| 700 | 1 | |a Soto-Angona, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Urrutia, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Inzoli, Benedetta |e verfasserin |4 aut | |
| 700 | 1 | |a González, Antonia López |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Quiroga, Josep Antoni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology |d 2011 |g 22(2024), 1 vom: 29. Jan., Seite 159-168 |w (DE-627)NLM225213141 |x 1738-1088 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:159-168 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.9758/cpn.23.1097 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 29 |c 01 |h 159-168 | ||